• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Insight
11 min read 24th February 2021

‘HispaNICE’: the Creation of an ‘Independent Authority for the Evaluation of Health Practices and Policies’ Gathers Momentum

This blog summarises an initiative taken by more than 300 health economists and experts in support of the creation of an independent health technology assessment agency in Spain. Over three hundred academic researchers, professionals, and experts have recently signed a…

Pat-1-scaled-1
Patricia Cubi-Molla
Mireia from ISPOR
Mireia Jofre-Bonet
Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

This blog summarises an initiative taken by more than 300 health economists and experts in support of the creation of an independent health technology assessment agency in Spain.

Over three hundred academic researchers, professionals, and experts have recently signed a manifesto called ‘For a Hispa-NICE: now or never‘ in support of the creation of an agency for the evaluation of health care practices and policies, analogous to England’s National Institute for Health and Care Excellent (NICE).

The manifesto was signed by prominent experts from a number of sectors, such as Guillem López-Casasnovas (member of the Directors Board of the Bank of Spain since 2005, and former President of the International Health Economics Association, among others); Rafael Bengoa (former Minister of Health of the Basque Country, and member of OHE Policy Committee); Félix Lobo (President of the Spanish National Health System’s Advisory Committee on Pharmaceutical Provision Financing); former presidents of the department of health; presidents of various scientific societies and medical associations, as well as associations such as the Spanish Health Economics Association, and the Spanish Society of Public Health and Health Administration.

The signatories explained that the crisis brought on by COVID-19 has exposed important drawbacks of the Spanish National Health System (SNHS). The document focuses on what is arguably the most critical one: the absence of a structured and systematic implementation of evidence-based decisions related to the administration and financing of medications, diagnostic tests, creation of healthcare infrastructures and prioritisation rules.

The manifesto explains how this is not a need specific to Spain but to all healthcare systems that must objectively assess the safety, effectiveness, and costs of medications and health technologies, especially when some drugs may not be priced according to their true value.

The advocates of the HispaNICE take as a model NICE in England, the institution that carries out systematic evaluations of evidence relating to technologies’ clinical- and cost-effectiveness to advise the National Health Service (NHS) on its adoption of new and existing health technologies. As the English NICE, the HispaNICE would require its own legal identity, functional autonomy, and well-defined procedures and functions, which would be responsible for analysing healthcare services, their technologies, drugs and therapeutic indications, prevention and public health interventions, and other health policies, balancing health results with the costs they entail for the SNHS and for society as a whole. They suggest naming this agency the ‘Independent Authority for the Evaluation of Health Practices and Policies‘.

An innovation of this proposal with respect to similar existing agencies is the upfront inclusion of social benefits, i.e., they propose that its remit includes establishing whether the health and social benefits of a health intervention are worth the cost, based on the analysis of the scientific evidence available at any given time. The running of the institution should be governed by the principles of independence, technical rigor, and good governance, favouring the transparency of the options adopted and contributing to the accountability of public decisions.

This new independent organisation would complement the efficacy and safety assessment carried out by other institutions, such as those currently developed by the Spanish Agency of Medicines and Medical Devices. The new institution would also foster the participation of relevant stakeholders into assessment stages, notably connecting existing centres of expertise at the central and regional levels, academia, patient associations and healthcare and pharmaceutical industry. The main goal of the institution would be to provide evidence to inform healthcare authorities; the creation of such an institution would therefore signal rigour and commitment on the part of healthcare authorities to better manage healthcare services, in line with the evaluation work carried out by the Spanish Network of Agencies for the Evaluation of Healthcare Technologies and Services (RedETS)

Source: Rosa Vivanco Hidalgo (RedETS – Spanish medical device HTA network) presentation at http://www.aes.es/sesion-hispanice/

A combination of factors makes the creation of HispaNICE a pressing issue. First, it is a common belief that the financing of the NextGenerationEU program (the largest stimulus package ever financed through the EU budget) represents an unrepeatable opportunity for it. Second, Spain has an institutional framework established over a number of years, which could facilitate the creation of such an institution at the national level (see an excellent analysis of this landscape in Oliva-Moreno et al., 2020). Finally, it is essential to confront the reality that the SNHS is not sustainable in the long run unless the resources are used efficiently; and the systematic assessment of value for money of new technologies is a necessary condition for this. This is not just the case for Spain: without a regulatory system that makes decisions based on the economic evaluation of health, health care, and health technologies, a universal NHS is not sustainable.

HispaNICE: the time is now. No excuses.

 

  • Health Care Systems
  • Value, Affordability, and…
  • News Releases

Related Insights

Optimise_AdobeStock_576507456_landscape
  • Insight
  • April 2023

How Restrictive are NICE ‘Optimised’ Decisions?

Read more
Air balloon HTA v4
  • Insight
  • March 2023

Around The World in HTAs: Spain – Are We There Yet?

Read more
Blog 4
  • Insight
  • October 2022

The Economics of Antibiotics – Part 4: What Does the Antibiotics Market of the Future Look Like?

Read more
Slide3
  • Insight
  • October 2022

The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!